Stocktoria

Century Therapeutics, Inc. IPSC

Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-06-17
Chart by TradingView
3/9
Piotroski F — financial health
-6.53
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$109.2M$6.6M$2.2M$5.2M
Operating income-$17.3M-$138.1M-$146.5M-$133.8M-$94.9M
Net income-$9.6M-$126.6M-$136.7M-$130.9M-$95.8M
Operating cash flow-$103.9M-$110.1M-$88.3M$14.1M-$89.0M
Free cash flow-$104.7M-$110.3M-$102.1M-$16.6M-$134.0M
Total assets$223.7M$353.2M$360.7M$486.5M$437.4M
Total liabilities$64.8M$191.9M$175.9M$183.8M$41.1M
Shareholders' equity$158.9M$161.4M$184.8M$302.7M$396.2M
Ratios
Operating margin-15.8%-2096.5%-6556.9%-2574.2%
Net margin-8.8%-1920.9%-6115.1%-2518.4%
FCF margin-95.9%-1673.8%-4567.5%-318.4%
Return on assets-4.3%-35.8%-37.9%-26.9%-21.9%
Return on equity-6.0%-78.4%-74.0%-43.2%-24.2%
Debt / equity0.01×0.02×
Current ratio5.971.509.9210.7214.57
Revenue growth1556.8%194.8%-57.0%

Notable holders (13F)

InvestorSharesValue
Point72 Asset Management, L.P.5,964,678$13.5M
RENAISSANCE TECHNOLOGIES LLC906,827$2.0M

Why these scores methodology →

Piotroski F-score: 3/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -6.53 (distress)

  • Working capital / assets 0.449
  • Retained earnings / assets -3.54
  • EBIT / assets -0.077
  • Equity / liabilities 2.454

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001850119 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.